尿激酶生脉注射液联合治疗不稳定性心绞痛的临床研究

CLINICAL STUDY OF COMBINED USE OF UROKINASE AND SHENGMAI INJECTION IN TREATING UNSTABLE ANGINA PECTORIS

目的探讨采用小剂量的尿激酶联合生脉注射液治疗不稳定性心绞痛(UAP)的临床效果。方法将120例患者随机分为两组,治疗组应用尿激酶和生脉注射液;对照组给与低分子肝素钠。观察治疗前、后患者的症状和实验室检查项目。结果治疗组总有效率达93.33%,并且对降低血小板最大聚集率(MPAR)、血小板颗粒膜糖蛋白(GMP-140)、左室射血分数及心电图的变化等效果明显(P<0.05)。结论尿激酶和生脉注射液联合应用治疗不稳定性心绞痛效果明显、稳定,具有广阔的临床前景。

Objective To explore the curative effects of the combined use of low dosage of urokinase and shengmai injection, a traditional chinese medicine in treating unstable angina pectoris（UAP）. Methods 120 cases were randomly divided into the treatment group treated with urokinase and shengmai injection and the contrast group treated with low molecular heparin sodium. The symptoms and lab examination results were observed and analyzed. Results The total curative rate was 93.33 %. The combined use of urokinase and shengmai injection produced good effects on GMP - 140, left ventricular ejection fraction and electroeardiographic changes（ P 〈 0.05）. Conclusion The combined use of urokinase and shengmai injection can produce good effects on UAP and deserves to be widely used.